Climbing plants are useful additions to our outside spaces. Even in small terraces or on balconies, growing vertically can maximize greenery. Think fragrant jasmine flowers perfuming the air in ...

There's nothing more stunning than a glorious flowering vine growing over a trellis or covering an ugly fence. But choosing the right species of vining plant to grow in your yard is vital so that you ...

Akebia Therapeutics gets EMA panel support for Xoanacyl to treat high phosphate & iron deficiency in CKD. Read more here.

CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted ...

CAMBRIDGE, Mass. - Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical firm focused on kidney disease treatments with a market capitalization of $456 million and impressive gross margins ...

Charles Schwab Investment Management Inc. raised its stake in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA – Free Report) by 3.2% during the fourth quarter, HoldingsChannel reports.

Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to break-even earnings per share a year ago.

Jefferies Financial Group assumed coverage on shares of Akebia Therapeutics (NASDAQ:AKBA – Free Report) in a research note issued to investors on Tuesday, Marketbeat reports. The firm issued a ...

Akebia plans to kick off a phase 3 trial to assess Vafseo as a potential treatment for anemia in late-stage CKD patients who aren’t on dialysis.

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Akebia Therapeutics Inc. (AKBA) on Thursday reported a fourth-quarter loss of $22.8 million, after reporting a profit in the same period a year ...